Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VASOPRESSIN V1B RECEPTOR ANTAGONIST · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Twice daily |
| SSR149415 - 100mg | EXPERIMENTAL | Twice daily |
| SSR149415 - 250mg | EXPERIMENTAL | Twice daily |
| Name | Type | Description |
|---|---|---|
| VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415) | DRUG | Pharmaceutical form: Capsule Route of administration: oral |
| Placebo | DRUG | Pharmaceutical form: Capsule Route of administration: Oral |
Inclusion criteria : * Diagnosis of major depressive disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition-Text Revision (DSM-IV-TR) and the Mini International Neuropsychiatric Interview (MINI) criteria. Exclusion criteria: * Outpatients unwilling to be hos...
Top 20 of 29 competitors
VASOPRESSIN V1B RECEPTOR ANTAGONIST is an investigational small molecule being developed for the treatment of Major Depressive Disorder. It is a vasopressin V1b receptor antagonist, and it is currently in Phase 2 clinical development.
VASOPRESSIN V1B RECEPTOR ANTAGONIST targets the vasopressin V1b receptor. By blocking this receptor, the drug is intended to modulate the hypothalamic-pituitary-adrenal axis, which is relevant to the pathophysiology of Major Depressive Disorder.
VASOPRESSIN V1B RECEPTOR ANTAGONIST is being developed by Sanofi, a company listed on the stock exchange under the ticker SNY. The drug is currently in Phase 2 clinical development for Major Depressive Disorder.
VASOPRESSIN V1B RECEPTOR ANTAGONIST is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed for Major Depressive Disorder.
VASOPRESSIN V1B RECEPTOR ANTAGONIST has one completed Phase 2 trial, identified as NCT01606384. This trial evaluated the potential effects of the drug on the hypothalamic-pituitary-adrenal axis in outpatients with Major Depressive Disorder, enrolling 100 participants in the United States.
Yes, VASOPRESSIN V1B RECEPTOR ANTAGONIST is also known as SSR149415. The completed Phase 2 trial NCT01606384 evaluated the effects of SSR149415 on the hypothalamic-pituitary-adrenal axis in patients with Major Depressive Disorder.